Following the success and approval of tirzepatide (Mounjaro, Eli Lilly, Indianapolis, IN, USA) in 2022 by FDA for treatment of T2DM, the SURMOUNT programme investigated its use as an anti-obesity medication in those without diabetes
If muscle symptoms are severe or persistent despite these interventions, clinicians should consider laboratory evaluation including creatine kinase, comprehensive metabolic panel with separate magnesium and calcium testing, thyroid function tests, vitamin D levels, and vitamin B12 levels to exclude alternative diagnoses
Tailored for humans, it achieved the FDAs approval list in 2017 for the treatment of type 2 diabetes
Activating these receptors protects nerve cells from damage and calms inflammation in the brain, just as they do throughout the body